Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAM-NK Cells in Relapsed/Refractory Multiple Myeloma and Non-Hodgkin Lymphoma
NCT03019666Phase 1Completed
- Sponsor
- Masonic Cancer Center
- Start
- Oct 2017
- Primary completion
- Aug 2022
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of nicotinamide-expanded natural killer cells in multiple myeloma (MM) and non-Hodgkin lymphoma (NHL), sponsored by Masonic Cancer Center. Started Oct 2017; status: completed.
02
Drugs
nicotinamide-expanded natural killer cells
03
Conditions
multiple myeloma (MM)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03019666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03019666.